Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas

BusinesswireApr 29 20:00

Foghorn Therapeutics Names Kristian Humer CFO

Foghorn Therapeutics (FHTX) said Tuesday that Kristian Humer has been named chief financial officer, effective immediately. Humer most recently served as CFO and chief business officer at Viridian The

MT NewswiresApr 16 20:16

Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME), Arvinas Holding Company (ARVN) and Viridian Therapeutics (VRDN)

TipRanksApr 12 19:10

Buy Rating Affirmed for Viridian Therapeutics Amidst TED Treatment Market Potential

TipRanksApr 5 20:55

VIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm

PHILADELPHIA, March 29, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Viridian Therapeutics, Inc. (NASDAQ: VRDN) ("Viridian") on behalf of the company's shareholders. The in

PR NewswireMar 29 21:00

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), OmniAb (OABI) and Vericel (VCEL)

TipRanksMar 25 09:40